Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2 - a prospective study.
about
Adjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care?Meroxest improves the prognosis of immunocompetent C57BL/6 mice with allografts of E0771 mouse breast tumor cells.Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors.More than 9 years of continuous trastuzumab treatment in metastatic breast cancer without cardiac toxicity: a case report and literature review.Prognostic role of troponin and natriuretic peptides as biomarkers for deterioration of left ventricular ejection fraction after chemotherapy.The influence of steroid receptor status on the cardiotoxicity risk in HER2-positive breast cancer patients receiving trastuzumab.Clinicopathologic characteristics and prognostic factors for HER2-positive patients with metastatic breast cancer in southern China.Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer.Continuous Trastuzumab Therapy in Breast Cancer Patients With Asymptomatic Left Ventricular Dysfunction.Increases in Xu Zheng and Yu Zheng among Patients with Breast Cancer Receiving Different Anticancer Drug Therapies.Cardiotoxicity of anthracycline therapy: current perspectivesImmunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in invasive breast cancer in women.Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancerThe antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytes.Echocardiographic signs of right ventricle changes after Trastuzumab treatment in breast cancer patients with erb-2 overexpression.Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting.Breast cancer treatment-induced cardiotoxicity.Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy.Application of artificial neural networks for predicting presence of non-sentinel lymph node metastases in breast cancer patients with positive sentinel lymph node biopsies.The use of trastuzumab in New Zealand women with breast cancer.Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival.Trastuzumab-related cardiac events in the treatment of early breast cancer.CATCH-KB: Establishing a Pharmacogenomics Variant Repository for Chemotherapy-Induced Cardiotoxicity.
P2860
Q27025860-70530D4E-825D-4ECC-9626-85371CC83D2FQ31134354-0C39C5DB-0D45-42E2-B7F9-7C94E0F3D67DQ33949465-B93EA5B6-B4C7-45DB-A595-977CF4AAC133Q34394390-097AEA7B-7994-486D-81B6-07EF3FEE3A10Q34466688-6779A30D-7B56-4B49-A645-A32AF76728EEQ35582848-91904534-A1DA-480D-B2D8-47AC46240EEBQ35829230-8EC63ED0-8641-447D-96D3-0B4420E864B0Q35880224-40881621-D13E-47DC-A6D6-2F5537940CF6Q36116313-CCB1591D-DAAD-4166-A188-E836411F0274Q36746331-23F5FB2B-2AAD-4DCF-847E-499F6F90B8AEQ36845348-417E924B-2C5F-4927-82BD-FF09C9BD2F23Q36983960-E9E7658D-3A6E-4902-9331-19AC03B05284Q37145885-F7D4CBDC-80F2-4835-BE3D-298E8265AD05Q37592520-45E1160C-D4C3-4D60-9349-69746F08BCE8Q37680612-E26AFA3B-8658-4AC9-9B85-956A7A516A45Q38639456-6BA1F73B-B75E-446D-8FF7-31CF63060917Q39428826-BF53554B-612C-46DA-A468-9B1E911E6E6CQ46388405-4CC2D237-58F7-44A0-B529-A062D8C43BE1Q47112525-AE7F1E6A-4BEE-448F-8542-F8314CB54803Q48150633-8647FA8D-FC1E-402B-9627-2C725D5C24B5Q51132740-28E1EE66-784E-45AD-85F7-8857B28EA54BQ54705428-5C0C9F73-D6B5-47CD-8B44-2F19DA7994F9Q55208199-D70DF869-1C61-48A4-B1A0-D4A5AD1870DD
P2860
Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2 - a prospective study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Cardiac complications associat ...... type 2 - a prospective study.
@ast
Cardiac complications associat ...... type 2 - a prospective study.
@en
type
label
Cardiac complications associat ...... type 2 - a prospective study.
@ast
Cardiac complications associat ...... type 2 - a prospective study.
@en
prefLabel
Cardiac complications associat ...... type 2 - a prospective study.
@ast
Cardiac complications associat ...... type 2 - a prospective study.
@en
P2093
P2860
P50
P356
P1476
Cardiac complications associat ...... type 2 - a prospective study.
@en
P2093
Grzegorz Piotrowski
Piotr Potemski
Rafał Gawor
P2860
P304
P356
10.5114/AOMS.2012.28549
P577
2012-05-01T00:00:00Z